収録コレクション： 投資家向けプレゼン資料の実例
Gilead Q3 2026 Earnings Presentation: the 36-slide deck Gilead Sciences used on its October 29, 2026 earnings call, covering Q3 2026 total product sales of $8.3B (+13% YoY), base business growth of 16% YoY, HIV sales of $6.25B (+18%), the Bixlenvo launch, the raised FY26 guidance, and a full pipeline update across HIV, oncology, cell therapy and inflammation.
このスライドの表紙をスタイルの参考にして、ご自身の内容からスライドを作成します。 下のページから好きな1枚を選び、そのレイアウトを参考にすることもできます。
クイックナビゲーション
タグ
スライドを共有
Gilead Q3 2026 Earnings Presentation: the 36-slide deck Gilead Sciences used on its October 29, 2026 earnings call, covering Q3 2026 total product sales of $8.3B (+13% YoY), base business growth of 16% YoY, HIV sales of $6.25B (+18%), the Bixlenvo launch, the raised FY26 guidance, and a full pipeline update across HIV, oncology, cell therapy and inflammation.
レイアウト、主要コンテンツ、視覚要素を含む各スライドページの詳細ビュー。
Title slide for Gilead's Q3 2026 financial results, dated October 29, 2026, with the Gilead 'Creating Possible' logo.
Left-aligned large navy title and date on white background; right side filled with staggered teal-to-navy gradient pill shapes.
Safe-harbor disclaimer under the Private Securities Litigation Reform Act of 1995, citing risks including IRA Medicare Part D pricing reform and the Biktarvy Maximum Fair Price determination, expiring ACA subsidies, the most-favored-nation pricing agreement with the U.S. government, tariffs, the announced PepStar acquisition, clinical holds, and trials such as PURPOSE-365 and SWIFT; followed by a list of Gilead trademarks including Bixlenvo, Yeztugo and Livdelzi.
Title at top with two dense full-width justified text paragraphs.
Agenda listing Key Takeaways (pages 4-5), Commercial Results (6-14), Pipeline Updates (15-20), Financial Results (21-27) and Appendix (29-36).
Vertical list of five section names on the left, each connected by a faint line to a gradient pill showing the page range.
Section divider introducing Daniel O'Day, Chairman & Chief Executive Officer.
Logo top-left, section title and speaker name/title on the left; large portrait photo in a rounded teal-to-navy gradient frame on the right.
Three numbered panels. Business Performance: base business up 16% YoY (strongest in over 10 years), HIV up 18% with Biktarvy up 10% and PrEP growing ~2x, Oncology up 9%, FY26 base business now expected to grow 10-11% and HIV 12%. Clinical Updates: Phase 2 SWIFT data for emvistegrast in ulcerative colitis at UEGW 2026, 2H26 updates for edecesertib and gamgertamig, two Phase 2 PULSAR trials of GS-3242 plus lenacapavir and two Phase 3 DAYBREAK trials of LEN plus bNAbs initiated. Commercial Launches: Bixlenvo launched in the U.S. in August, Trodelvy plus pembro approved in Europe for 1L PD-L1+ mTNBC, anito-cel PDUFA December 23 for 4L+ R/R MM, and a Yeztugo weekly oral decision expected February 2027.
Three stacked rounded-rectangle panels, each with a navy numbered circle, a bold category label and four bullets; abbreviation footnote at bottom.
Section divider introducing Johanna Mercier, Chief Commercial & Corporate Affairs Officer.
Same divider template: title and speaker on the left, portrait in rounded gradient frame on the right.
Pie chart of Q3 2026 product sales by franchise: HIV $6.2B (+18% YoY), Veklury $86M (-69%), Trodelvy $506M (+42%), Cell Therapy $355M (-18%), Liver Disease $927M (+13%), Other $167M (-9%). Headline figures: total product sales excluding Veklury $8.2B (+16% YoY, +8% QoQ), total product sales $8.3B (+13% YoY, +9% QoQ), HIV $6.2B (+18% YoY, +10% QoQ), Oncology $860M (+9% YoY, -2% QoQ).
Legend with values on the far left, large pie chart center-left, four large KPI figures with labels stacked on the right split by a dotted divider.
Stacked bar chart of HIV product sales by region over five quarters: Q3 2025 $5,277M, Q4 2025 $5,801M, Q1 2026 $5,030M, Q2 2026 $5,693M, Q3 2026 $6,249M (U.S. $5,261M, Europe $591M, Rest of World $397M). Q3 sales of $6.25B grew 18% YoY, driven by higher realized price, demand and favorable inventory dynamics; 2026 HIV growth expectation raised to 12% from 9-10%.
Five-quarter stacked bar chart on the left; two big KPIs ($6.25B, +18%) and three bullets on the right.
Biktarvy Q3 2026 sales of $4.1B (+10% YoY, +8% QoQ), the #1 regimen for naive and switch patients in most major markets with ~53% U.S. treatment market share, an all-time high. Bixlenvo (bictegravir 75mg/lenacapavir 50mg) was FDA approved August 27, 2026 for virologically suppressed adults; 5-6% of people with HIV are on complex regimens and up to 20% switch therapies annually; it is the smallest single-tablet regimen for HIV treatment with rapid initial uptake.
Two side-by-side grey rounded panels, each topped with a product logo pill; each holds stat boxes on the left and bullets on the right.
PrEP sales grew ~2x YoY while the U.S. PrEP market grew ~14%. Yeztugo (lenacapavir injection) Q3 sales $305M (+31% QoQ), now the leading injectable PrEP regimen in the U.S. with >70% 12-month persistency and on track for ~$1B FY26 sales. Descovy Q3 sales $1.0B (+49% YoY, +8% QoQ), with ~80% of Descovy sales for PrEP.
Two headline stats across the top separated by a dotted vertical line; two product panels below with logo pills, sales line and bullets.
Stacked bar chart of Liver Disease sales by PBC, HCV, HBV and HDV: Q3 2025 $819M rising to Q3 2026 $927M (PBC $203M, HCV $320M, HBV $350M, HDV $53M). Livdelzi Q3 sales $203M (+93% YoY, +21% QoQ) with >50% U.S. 2L PBC market share. Total Liver +13% YoY and +6% QoQ.
Stacked bar chart on the left; Livdelzi logo pill with two KPIs and bullets in a grey panel on the right, plus two more bullets below.
Trodelvy sales by region rose from $357M in Q3 2025 to $506M in Q3 2026 (U.S. $336M, Europe $98M, Rest of World $71M), +42% YoY and +11% QoQ on demand in mTNBC and pre-treated HR+/HER2- mBC. Trodelvy holds the #1 share in 2L mTNBC and is the first and only ADC approved for 1L mTNBC across PD-L1 status in the U.S. and Europe.
Stacked regional bar chart on the left; Trodelvy logo pill with two green KPIs (+42%, #1) and bullets on the right.
Yescarta and Tecartus sales fell from $432M in Q3 2025 to $355M in Q3 2026 (Yescarta $294M, Tecartus $60M), -18% YoY and -15% QoQ on competitive headwinds. More than 37K patients treated to date at over 600 authorized treatment centers; anito-cel 4L+ R/R MM PDUFA date December 23, 2026 with launch preparations underway.
Two-segment stacked bar chart on the left; Yescarta/Tecartus logo pill with two purple KPIs and bullets on the right.
Launch timeline: approved products Livdelzi (2L PBC), Trodelvy (1L mTNBC), Yeztugo (HIV PrEP twice-yearly injection), Hepcludex (HDV) and newly approved Bixlenvo (VS PWH); anito-cel for 4L+ R/R MM expected December 2026; Yeztugo weekly oral PrEP expected February 2027; ISL/LEN weekly for virally suppressed PWH expected 2027.
Four columns (Approved, December 2026, February 2027, 2027) with product logo cards, overlaid with a rising navy arrow carrying milestone circles.
Section divider introducing Dietmar Berger, MD, PhD, Chief Medical Officer.
Standard divider: title and speaker on the left, portrait in rounded gradient frame on the right.
Roadmap of lenacapavir-based programs across 2026, 2027 and 2028+. Treatment: Bixlenvo daily oral U.S. launch in 2026, EC decision 2027; islatravir + lenacapavir weekly oral met primary endpoints June 2026, launch 2027; LEN + GS-3242 / GS-1720 weekly oral Phase 2 first patient Q4 2026 and early 2027, launch 2030; GS-3107 + INSTI monthly oral on Phase 1 clinical hold, launch 2031-2033; LEN + TAB + ZAB twice-yearly injectable with Phase 3 DAYBREAK-1 and -2 initiated Q3 2026, launch 2030; LEN + GS-3242 twice-yearly with Phase 2 PULSAR-1 and -2 initiated Q2 2026, launch 2031-2033. PrEP: weekly oral lenacapavir U.S. launch February 2027; once-yearly injectable PURPOSE 365 Phase 3 update 2027, launch 2028.
Swimlane table: dosing-frequency labels on the left, color-coded program pills, and milestone outlines across a 2026/2027/2028+ map-pin timeline; star icons mark new disclosures.
Seven ongoing clinical-stage ADC programs. Tubutecan platform: GS-8823 5T4-ADC in advanced cancers (Phase 1), GS-8824 NAPISTAR-1-02 in 2L+ PSOC (Phase 1), GS-8824 NAPISTAR-1-01 in 2L+ PROC and NAPISTAR-1-03 in 2L+ EC (Phase 2, new disclosure). Trodelvy: EVOKE-SCLC 2L ES-SCLC, ASCENT-05 high-risk early TNBC and ASCENT-GYN 2L+ EC in Phase 3; approved in ASCENT-03/04 1L mTNBC, ASCENT 2L+ mTNBC and TROPiCS-02 pre-treated HR+/HER2- mBC.
Four chevron phase headers (Phase 1, 2, 3, Approved) above colored program tiles; large '7' callout and text on the right.
Inflammation and immunology programs in four columns. IBD: emvistegrast (alpha4beta7) Phase 2 data at UEGW with Phase 3 first patient in 2027 in UC, GS-5290 (TLP2) Phase 2 PALEKONA in UC, GS-8670 (FXR agonist) and GS-1384 (IL-10R) Phase 1 in IBD, and an IL-23 oral program via the announced HCXT-2001 acquisition. B-cell mediated: gamgertamig (BCMAxCD3) Phase 1/2 update in 2H26 in ITP, KITE-363 Phase 1 in autoimmune diseases, anito-cel Phase 1 in gMG, IIM and MS. Lupus: edecesertib (IRAK4) Phase 2 COSMIC update at ACR in November in CLE. Type 2 inflammatory: GS-5305 (CD200R) Phase 1 in atopic dermatitis. Liver and other: Livdelzi Phase 3 IDEAL update at AASLD in November, GS-4571 (GLP-1) Phase 1 in metabolic diseases, GS-6791 (IRAK4) and GS-0151 (PD-1) Phase 1 in rheumatoid arthritis.
Four colored column headers with stacked white program cards beneath; star badges flag new disclosures.
Anito-cel in multiple myeloma: iMMagine-1 4L+ R/R MM PDUFA December 23, 2026; iMMagine-3 2-4L R/R MM filing as early as 2027; iMMagine-4 TNE NDMM and iMMagine-6 TE MM initiations expected 2027. Other programs: KITE-512 Phase 1 in hepatocellular cancer with initiation expected soon; autoimmune ARC-311 (anito-cel) and HERMOSA-1 and -2 (KITE-363) in rheumatology and neurology; KITE-753 PALISADES-1 and -2 in 2L and 3L+ R/R DLBCL on partial clinical hold; in vivo CAR T investigator-initiated trial with dosing initiated in Q3 2026 in China.
Navy banner over a row of four trial cards, then four colored category headers with cards beneath.
Milestone tracker. 1H26 completed: ISLEND-1 and ISLEND-2 Phase 3 updates for weekly oral ISL/LEN, Hepcludex MYR301 FDA decision in HDV. 2H26: Bixlenvo ARTISTRY-1 & -2 FDA decision completed; Trodelvy ASCENT-03 and ASCENT-04 FDA decisions completed; ASCENT-GYN Phase 3 update on track; EVOKE-03 in 1L mNSCLC completed but did not meet its primary endpoint and was discontinued (data at WCLC September 2026); anito-cel iMMagine-1 FDA decision on track; Livdelzi IDEAL Phase 3 update completed.
Two tables (1H26, 2H26) with columns Program, Trial, Indication, Update and Status; status icons legend top-right.
Section divider introducing Andrew Dickinson, Chief Financial Officer.
Standard divider: title and speaker on the left, portrait in rounded gradient frame on the right.
Product sales rose from $7,345M in Q3 2025 (base $7,068M, Veklury $277M) to $8,289M in Q3 2026 (base $8,203M, Veklury $86M). Base business +16% YoY and +8% QoQ on HIV, Trodelvy and Livdelzi, partly offset by Cell Therapy; total product sales +13% YoY and +9% QoQ, reflecting lower Veklury (-69%) on fewer COVID-19 hospitalizations.
Two stacked bars with an arrow annotation on the left; two headline statements with supporting bullets on the right.
Non-GAAP table Q3 2025 vs Q3 2026 ($M): COGS $992 to $983; product gross margin 86% to 88% (+165 bps); R&D $1,334 to $1,591 (+19%); acquired IPR&D $170 to $18 (-89%); SG&A $1,351 to $1,539 (+14%); operating expenses $2,856 to $3,148 (+10%); operating income $3,921 to $4,168 (+6%); operating margin 50% both years; tax rate 18% to 19%; net income $3,095 to $3,186 (+3%); diluted EPS $2.47 to $2.55 (+3%); diluted shares 1,254M to 1,251M. Commentary attributes R&D and SG&A growth to compensation accruals, clinical costs, HIV promotion and legal expenses; operating margin 49% YTD excluding IPR&D from the Arcellx, Tubulis and Ouro Medicines acquisitions.
Financial table on the left with highlighted subtotal rows; commentary bullets under two headings on the right.
EPS bridge: Q3 2025 non-GAAP diluted EPS $2.47, less $0.25 from a $400M increase in other revenue tied to an IP asset sale, gives an illustrative $2.22; plus $0.33 from higher product sales and lower acquired IPR&D, partly offset by higher OpEx, reaches Q3 2026 EPS of $2.55, i.e. 15% growth on the illustrative base.
Waterfall chart with three navy bars and two annotated delta boxes; single bullet on the right.
Guidance history across February 10, May 7, August 4 and October 29, 2026. October guidance: total product sales ~$31.0B-$31.3B; product sales ex-Veklury ~$30.7B-$31.0B; Veklury ~$300M; non-GAAP gross margin ~87%; R&D mid-to-high single-digit growth; acquired IPR&D ~$12.9B; SG&A high single-digit growth; operating income ~$2.0B-$2.4B; tax rate ~220%-165%; non-GAAP diluted EPS ~$(1.20)-$(0.85); GAAP diluted EPS ~$(4.40)-$(4.05). Base business guidance raised by $900M (up $1.65B since the start of the year), HIV now +12% and Yeztugo ~$1B; acquired IPR&D increase reflects ~$1.4B of Q4 upfront payments for the PepStar oral IL-23R inhibitor acquisition and the Vir collaboration.
Wide five-column guidance table with navy date headers on the left; two headed bullet groups on the right.
Bridge from August guidance of $(0.65)-$(0.30), adding back ~$9.15 of Q2 acquisitions and other revenues for illustrative August guidance of $8.50-$8.85; +$0.55 from higher base sales and $(0.30) from higher OpEx give illustrative October guidance of $8.75-$9.10; ~$9.95 of FY26 acquisitions and other revenues brings reported October guidance to $(1.20)-$(0.85). Excluding acquisitions, illustrative FY26 EPS is ~$8.93 at the midpoint, up ~$0.78 (+10%) from FY25 non-GAAP EPS of $8.15.
Floating-bar bridge chart with labeled grey adjustment bars and navy guidance bars; two bullets on the right.
About $1B of dividends paid in Q3 2026 and $370M of shares repurchased (2.6M shares at an average $139.84). Capital allocation priorities: invest in the business and R&D pipeline while managing expenses, continue ordinary-course partnerships and business development, grow the dividend, and repurchase shares to offset dilution and opportunistically reduce share count.
Two large stats stacked on the left; four arrow-marked priorities under a heading on the right.
Q&A slide featuring Daniel O'Day (Chairman & CEO), Johanna Mercier (Chief Commercial & Corporate Affairs Officer), Dietmar Berger, MD, PhD (Chief Medical Officer), Andrew Dickinson (CFO) and Cindy Perettie (EVP & Head of Kite).
Large 'Q&A' text on the left; five circular headshots with names and titles in a 3+2 grid.
Appendix pipeline grid showing 49 clinical programs and 4 clinical opt-in assets across Oncology, Viral Disease and Inflammatory Disease by phase. Named late-stage assets: SG in A/R EC and ES-SCLC, SG + pembro adjuvant TNBC, axi-cel 1L HR LBCL and 2L+ HR FL, anito-cel 2-4L and 4L+ R/R MM, KITE-753 2L DLBCL; LEN HIV PrEP LAI Q12M, Yeztugo HIV PrEP LAO QW, Bixlenvo HIV oral QD, LEN + TAB + ZAB HIV LAI Q6M, and ISL/LEN combo HIV LAO QW.
Grid of colored blocks per therapeutic area across Phase 1, Phase 2 and Phase 3/Filed/Approved columns; Kite programs marked with blue corner triangles, optionable partner programs in grey.
HIV prevention: Yeztugo HIV PrEP LAO QW (sNDA submitted), lenacapavir PURPOSE 365 Q12M. HIV treatment: Bixlenvo (NDA approved, FDA approval granted), islatravir/lenacapavir ISLEND-1 & -2, LEN + TAB + ZAB DAYBREAK 1 & 2 (moved Phase 2 to Phase 3, Breakthrough Therapy), GS-3242 + lenacapavir PULSAR 1 & 2 LAI Q6M and LAO QW (Phase 1 to Phase 2), GS-3107 capsid inhibitor on clinical hold. HIV cure: teropavimab + zinlirvimab, vesatolimod, GS-8588 bispecific T-cell engager, and new listing targeted IL-15 (GS-0415) with Phase 1 first patient in.
Pipeline table with Clinical Program and Indication columns, green progress bars across Phase 1 to Filed, and a Q3'26 Updates column; grey sub-category rows.
Phase 1 programs: HDV pre-S1 nAb (GS-4321), HBV therapeutic vaccine (GS-2829 + GS-6779), HSV helicase-primase inhibitor (GS-1179), coronavirus mPro inhibitor (GS-1701) for neglected and emerging viruses; opt-in: Assembly Biosciences with one clinical-stage HDV program.
Same pipeline table format with short Phase 1 bars and generous white space below.
Lymphoma: axi-cel ZUMA-22 (2L+ HR FL) and ZUMA-23 (1L HR LBCL) in Phase 3; KITE-753 PALISADES-2 (2L DLBCL) and PALISADES-1 (3L+ R/R DLBCL) on clinical hold with RMAT designation. Multiple myeloma: anito-cel iMMagine-1 (4L+ R/R MM, BLA filed) and iMMagine-3 (2-4L R/R MM, Phase 3). Autoimmune: KITE-363 HERMOSA-1 (rheumatology) and HERMOSA-2 (neurology), anito-cel ARC-311, all Phase 1. ZUMA-4 removed after data submission in September 2026 to fulfill the EU Pediatric Investigation Plan.
Pipeline table with blue bars for oncology programs and pink bars for autoimmune programs; Q3'26 updates column.
Sacituzumab govitecan-hziy (Trodelvy) in ASCENT-05 high-risk adjuvant TNBC, EVOKE-SCLC-04 2L ES-SCLC (Breakthrough Therapy) and ASCENT-GYN-01 A/R EC in Phase 3; NaPi2b ADC GS-8824 in NAPISTAR 1-01 (2L+ PROC), new listing NAPISTAR 1-03 (A/R EC, Phase 2 first patient in) and NAPISTAR 1-02 (2L+ PSOC); advanced cancers: efarindodekin alfa, 5T4 ADC GS-8823, anti-IL-18BP GS-0321, and new listing GS-1206 (Phase 1 first patient in). Denikitug Phase 2 in mCRC removed.
Pipeline table with slate-blue progress bars, grey sub-category rows and Q3'26 updates column.
Phase 1 advanced-cancer programs: MAT2A inhibitor (GS-2426), PARP1 inhibitor (GS-0201), PRMT5 inhibitor (GS-5319); opt-ins: Arcus with two clinical-stage programs and MacroGenics with one. Denikitug Phase 1 removed.
Short pipeline table with Phase 1 bars and opt-in rows; mostly white space.
Lupus: edecesertib (COSMIC) Phase 2. IBD: tilpisertib fosmecarbil (PALEKONA) and emvistegrast (SWIFT) Phase 2, FXR agonist GS-8670 Phase 1. Inflammatory diseases: gamgertamig Phase 2, CD200R agonist GS-5305, new listing IL-10R VHH GS-1384 (Phase 1 first patient in), IRAK4 degrader GS-6791 and PD1 agonist GS-0151 in Phase 1. Metabolic: GLP-1R agonist GS-4571 Phase 1.
Pipeline table with pink progress bars, grey sub-category rows and Q3'26 updates column.
As of September 30, 2026: total debt, net $26.23B; total adjusted debt $25.35B (after excluding the $1.06B royalty-sale liability). Trailing twelve months to September 30, 2026: net income attributable to Gilead $(3.86)B, with add-backs including $11.58B of initial costs of externally developed IPR&D and $2.15B of impairments, giving adjusted EBITDA of $14.18B and an adjusted debt to adjusted EBITDA ratio of ~1.79x (vs ~1.73x a year earlier). Footnote notes total interest expense and debt amortization expected to be $1B for FY2026.
Two stacked reconciliation tables (point-in-time debt and trailing-twelve-month EBITDA) across five quarter-end columns with the latest quarter highlighted; numbered footnotes.
このスライドと基礎となるプレゼンテーションコンテンツに関する一般的な質問。
Gilead reported Q3 2026 total product sales of $8.3B, up 13% year over year. Excluding Veklury, base business sales were $8.2B, up 16%, which the company calls its strongest growth in over 10 years. HIV sales were $6.25B (+18%) and non-GAAP diluted EPS was $2.55.
Yes. On October 29, 2026 Gilead raised FY26 total product sales guidance to ~$31.0B-$31.3B and lifted base business guidance by $900M, now expecting 10-11% base business growth and 12% HIV growth. Reported non-GAAP EPS guidance moved to ~$(1.20)-$(0.85) because of ~$12.9B of acquired IPR&D, while illustrative EPS excluding acquisitions is ~$8.93 at the midpoint.
Key items include the August 27, 2026 FDA approval of Bixlenvo, a December 23, 2026 PDUFA date for anito-cel in 4L+ relapsed or refractory multiple myeloma, an expected February 2027 decision on weekly oral Yeztugo for PrEP, the 2027 expected launch of weekly islatravir/lenacapavir, and new Phase 2 and Phase 3 trials of long-acting lenacapavir combinations.
It is Gilead Sciences' official Q3 2026 earnings presentation, published on the company's investor relations website for the October 29, 2026 earnings call. The original 36 slides are reproduced in full here for reference.
Yes. Both the original PDF and a PowerPoint (PPTX) conversion are available. The PPTX was converted from the PDF, so some charts and tables may come through as images or need light clean-up before you reuse them.
The Key Takeaways summary (page 5), the stacked regional sales charts (pages 8, 11-13), the launch roadmap (page 14), the swimlane HIV pipeline (page 16), the guidance history table (page 25) and the EPS bridge charts (pages 24 and 26) are the most reusable layouts for biotech or pharma investor presentations.
Chairman and CEO Daniel O'Day, Chief Commercial and Corporate Affairs Officer Johanna Mercier, Chief Medical Officer Dietmar Berger and CFO Andrew Dickinson presented, with Cindy Perettie, EVP and Head of Kite, joining for Q&A.
Official investor relations site hosting Gilead's quarterly earnings releases and presentations.
Create Your Own Slides
Turn your ideas into professional presentations in seconds with 2slides AI.
プロフェッショナルなデザインを参照し、スタイルを選択し、完璧なテキストレンダリングでスライドを生成。Nano Banana搭載—今すぐプレゼンテーションの作成を始めましょう。
© 2026 2slides。全著作権所有。
